PRME Prime Medicine, Inc.
Prime Medicine, Inc. (PRME) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.22 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -5.2% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Prime Medicine, Inc.
Prime Medicine Inc. is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies. Prime Medicine Inc. is based in CAMBRIDGE, Mass.
Sector
Healthcare
Industry
Biotechnology
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.